Oncology Today with Dr Neil Love

Featuring perspectives from Prof Chan Chea and Dr Matthew Matasar, including the following topics:Introduction (0:00)Prologue: Saturday Night Fever (1:35)Baby Boomers' Guide to Mechanisms of Action (3:07)Second-Line Treatment (12:36)Complications Associated with Bispecific Antibodies (23:41)Case Presentations (25:52)New Bispecific T-Cell Engagers — Surovatamig (26:24)Other Novel Agents (50:05)CME information and select publications

Featuring perspectives from Dr Sagar Lonial and Dr Paul G Richardson, including the following topics:Multiple Myeloma (0:00)Introduction: ESMO 2026; Recent FDA Approvals (1:53)Chimeric Antigen Receptor T-Cell Therapy — Dr Lonial (2:46)Bispecific Antibodies — Dr Lonial (19:16)Antibody-Drug Conjugates — Dr Richardson (37:08)Up-Front Treatment; Cereblon E3 Ligase Modulators — Dr Richardson (50:10)CME information and select publications

Featuring perspectives from Dr Neeraj Agarwal and Dr Emmanuel S Antonarakis, including the following topics:Introduction: ESMO 2026; Recent FDA Approvals (0:00)Selection of Endocrine Therapy — Dr Antonarakis (2:24)Utility of PARP Inhibitors — Dr Agarwal (22:59)AKT Inhibition for PTEN-Deficient Disease — Dr Antonarakis (35:42)Radiopharmaceuticals — Dr Agarwal (45:02)CME information and select publications

Featuring perspectives from Dr Charles E Geyer Jr, Dr Maryam Lustberg, Dr Rita Nanda and Dr Seth Wander, including the following topics:Breast Cancer Introduction: ESMO 2026; Recent FDA Approvals (0:00)ER-Positive Breast Cancer (5:01)HER2-Positive Breast Cancer (1:19:08)Triple-Negative Breast Cancer (1:48:54)CME information and select publications

Featuring an interview with Dr Matthew Lunning, including the following topics:Bispecific antibody/antibody-drug conjugate combinations (0:00)A man in his late 90s with mantle cell lymphoma — Ann LaCasce, MD, MMSc (8:07)CME information and select publications

Featuring a presentation by Dr Matthew Matasar, including the following topics:Selection of First-Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) (0:00)Clinician Survey Results Regarding First-Line Treatment of DLBCL (11:41)Current and Future Roles of Monoclonal and Bispecific Antibodies in Therapy for Relapsed/Refractory (R/R) DLBCL (16:01)Clinician Survey Results Regarding the Use of Monoclonal and Bispecific Antibodies for R/R DLBCL (28:47)Evidence-Based Incorporation of Antibody-Drug Conjugates (ADCs) into the Management of R/R DLBCL (34:34)Clinician Survey Results Regarding the Use of ADCs for R/R DLBCL (46:31)Discussion of Questions from the Community (50:20)CME information and select publications

Featuring an interview with Dr Matthew Lunning, including the following topics:A woman in her late 70s with non-GCB diffuse large B-cell lymphoma receives pola-R-CHP — Ann LaCasce, MD, MMSc (0:00)CNS prophylaxis in non-Hodgkin lymphoma (7:58)CME information and select publications

Featuring an interview with Dr Erica Mayer, including the following topics:Risk Assessment and Genomic Assays for Hormone Receptor (HR)-Positive, HER2-Negative Localized Breast Cancer (0:00)Investigator Survey Results on Risk Assessment and Genomic Assays (20:07)Adjuvant CDK4/6 Inhibitors for High-Risk, HR-Positive, HER2-Negative Localized Breast Cancer (24:30)Investigator Survey Results on Adjuvant CDK4/6 Inhibitors (30:42)Tolerability and Other Practical Considerations with Adjuvant CDK4/6 Inhibitor Therapy (32:07)Investigator Survey Results on Tolerability and Other Practical Considerations with Adjuvant CDK4/6 Inhibitor Therapy (37:44)Adjuvant Oral Selective Estrogen Receptor Degraders (SERDs) for HR-Positive, HER2-Negative Localized Breast Cancer (39:05)Investigator Survey Results on Adjuvant Oral SERDs (43:02)Discussion of Questions from the Community (45:00)CME information and select publications

Featuring perspectives from Dr Lindsey Roeker, including the following topics:Case: A man in his mid 60s with TP53-aberrant chronic lymphocytic leukemia (CLL) with extensive marrow infiltration receives first-line venetoclax/obinutuzumab and experiences an excellent response (0:00)Case: A man in his late 70s with small lymphocytic lymphoma (SLL) and cardiovascular comorbidities requiring verapamil and anticoagulation receives acalabrutinib/venetoclax; Case: A man in his early 80s with SLL receives zanubrutinib/sonrotoclax as part of the CELESTIAL-TNCLL trial (14:46)Case: A man in his late 70s with progressive CLL worsening after a skiing injury receives acalabrutinib/venetoclax as part of the MAJIC trial (22:37)CME information and select publications

Featuring perspectives from Dr Lindsey Roeker, including the following topics:Consensus Approach to optimizing front-line treatment (0:00)Emerging role of sonrotoclax (8:39)Bruton tyrosine kinase inhibitor monotherapy for older patients; discontinuation (14:48)Evolving role of minimal residual disease assessment (19:16)CME information and select publications